Vinehealth secures £4.2m in seed funding led by Talis Capital to scale operations.
The financing round was led by Talis Capital with participation from multiple angels and existing backers.
Vinehealth operates a digital health platform that combines behavioural science and artificial intelligence to support cancer patients. The technology enables individuals to self-manage medications and symptoms while generating structured outcome data for clinical and pharmaceutical research.
London-based digital health startup Vinehealth has secured £4.2m in seed funding to advance its product capabilities and expand its presence in the United States. The round was led by Talis Capital, with participation from existing backers Playfair Capital and Ascension. A cohort of prominent angel investors also contributed to the financing. The capital follows previous grant awards, including funding from Innovate UK, and arrives as the company builds out its presence across the oncology sector.
From the founder
"We are delighted to have received such credible investor support to continue on our mission to empower and support those with cancer. It’s imperative that we start understanding how therapies are affecting patients: for pharmaceutical companies, our technology enables deeper patient understanding which leads to better drugs, greater differentiation and faster licensing, as well as the ability to provide personalised scalable support to patients. For patients, this means better care and improved outcomes from cancer. We’re now looking forward to applying our rich data and machine learning capabilities to novel predictive analytics to generate even richer insights for our life science partners."
Rayna Patel
Founder and CEO at Vinehealth
Investor perspective
"We’re hugely excited to be partnering with Rayna and Georgina: we’d been keeping a close eye on Vinehealth’s growth for several months before we invested in the company, given its unique value proposition where healthcare outcomes work in direct correlation with financial outcomes. It’s a win-win-win for patients, hospitals and pharmaceutical companies, which is rarely the case in the healthcare space where parties are often at odds with one another."
Beatrice Aliprandi
Principal, Talis Capital
Use of funds
- 01Continue product development
- 02Grow the team
- 03Expand into international markets
Investors
Categories
About the company
Vinehealth
Vinehealth provides a digital platform that supports cancer patients and collects clinical outcome data.